Literature DB >> 15367396

Reducing plasma HIV RNA improves muscle amino acid metabolism.

Kevin E Yarasheski1, Samuel R Smith, William G Powderly.   

Abstract

We reported (Yarasheski KE, Zachwieja JJ, Gischler J, Crowley J, Horgan MM, and Powderly WG. Am J Physiol Endocrinol Metab 275: E577-E583, 1998) that AIDS muscle wasting was associated with an inappropriately low rate of muscle protein synthesis and an elevated glutamine rate of appearance (Ra Gln). We hypothesized that high plasma HIV RNA caused dysregulation of muscle amino acid metabolism. We determined whether a reduction in HIV RNA (> or =1 log) increased muscle protein synthesis rate and reduced R(a) Gln and muscle proteasome activity in 10 men and 1 woman (22-57 yr, 60-108 kg, 17-33 kg muscle) with advanced HIV (CD4 = 0-311 cells/microl; HIV RNA = 10-375 x 10(3) copies/ml). We utilized stable isotope tracer methodologies ([13C]Leu and [15N]Gln) to measure the fractional rate of mixed muscle protein synthesis and plasma Ra Gln in these subjects before and 4 mo after initiating their first or a salvage antiretroviral therapy regimen. After treatment, median CD4 increased (98 vs. 139 cells/microl, P = 0.009) and median HIV RNA was reduced (155,828 vs. 100 copies/ml, P = 0.003). Mixed muscle protein synthesis rate increased (0.062 +/- 0.005 vs. 0.078 +/- 0.006%/h, P = 0.01), Ra Gln decreased (387 +/- 33 vs. 323 +/- 15 micromol.kg fat-free mass(-1).h(-1), P = 0.04), and muscle proteasome chymotrypsin-like catalytic activity was reduced 14% (P = 0.03). Muscle mass was only modestly increased (1 kg, P = not significant). We estimated that, for each 10,000 copies/ml reduction in HIV RNA, approximately 3 g of additional muscle protein are synthesized per day. These findings suggest that reducing HIV RNA increases muscle protein synthesis and reduces muscle proteolysis, but muscle protein synthesis relative to whole body protein synthesis rate is not restored to normal, so muscle mass is not substantially increased.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367396      PMCID: PMC3170408          DOI: 10.1152/ajpendo.00359.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  43 in total

1.  Dyslipidemia due to retroviral protease inhibitors.

Authors:  Anthony D Kelleher; Andrew K Sewell; David A Price
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

Review 2.  Relation between glutamine, branched-chain amino acids, and protein metabolism.

Authors:  Milan Holecek
Journal:  Nutrition       Date:  2002-02       Impact factor: 4.008

3.  Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.

Authors:  Tomas Cihlar; Gabriel Birkus; Dale E Greenwalt; Michael J M Hitchcock
Journal:  Antiviral Res       Date:  2002-04       Impact factor: 5.970

4.  Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study.

Authors:  R H Clark; G Feleke; M Din; T Yasmin; G Singh; F A Khan; J A Rathmacher
Journal:  JPEN J Parenter Enteral Nutr       Date:  2000 May-Jun       Impact factor: 4.016

5.  Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women.

Authors:  A Y McDermott; A Shevitz; T Knox; R Roubenoff; J Kehayias; S Gorbach
Journal:  Am J Clin Nutr       Date:  2001-11       Impact factor: 7.045

6.  HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.

Authors:  J S Liang; O Distler; D A Cooper; H Jamil; R J Deckelbaum; H N Ginsberg; S L Sturley
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

7.  Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Authors:  C A Wanke; M Silva; T A Knox; J Forrester; D Speigelman; S L Gorbach
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

8.  Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.

Authors:  Gabriel Birkus; Michael J M Hitchcock; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Resistance exercise acutely increases MHC and mixed muscle protein synthesis rates in 78-84 and 23-32 yr olds.

Authors:  D L Hasten; J Pak-Loduca; K A Obert; K E Yarasheski
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-04       Impact factor: 4.310

10.  The human 26S proteasome is a target of antiretroviral agents.

Authors:  Marco Piccinini; Maria T Rinaudo; Nadia Chiapello; Emanuela Ricotti; Simone Baldovino; Michael Mostert; Pier-Angelo Tovo
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

View more
  22 in total

1.  Maternal post-absorptive leucine kinetics during late pregnancy in US women with HIV taking antiretroviral therapy: a cross-sectional pilot study.

Authors:  W Todd Cade; Gautam K Singh; Mark R Holland; Dominic N Reeds; E Turner Overton; Nancy Cibulka; Karen Bahow; Rachel Presti; Andrea Stephens; Alison G Cahill
Journal:  Clin Nutr ESPEN       Date:  2015-08-01

2.  Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo.

Authors:  Randall J Bateman; Ling Y Munsell; John C Morris; Robert Swarm; Kevin E Yarasheski; David M Holtzman
Journal:  Nat Med       Date:  2006-06-25       Impact factor: 53.440

3.  Alternative equations for whole-body protein synthesis and for fractional synthetic rates of proteins.

Authors:  Rajasekhar Ramakrishnan
Journal:  Metabolism       Date:  2007-11       Impact factor: 8.694

4.  Skeletal and cardiac myopathy in HIV-1 transgenic rats.

Authors:  Anne M Pruznak; Ly Hong-Brown; Rachel Lantry; Pengxiang She; Robert A Frost; Thomas C Vary; Charles H Lang
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-08-19       Impact factor: 4.310

5.  A combined chemometric and quantitative NMR analysis of HIV/AIDS serum discloses metabolic alterations associated with disease status.

Authors:  Tracy R McKnight; Hikari A I Yoshihara; Lungile J Sitole; Jeffery N Martin; Francois Steffens; Debra Meyer
Journal:  Mol Biosyst       Date:  2014-11

6.  Age-related skeletal muscle decline is similar in HIV-infected and uninfected individuals.

Authors:  Kevin E Yarasheski; Rebecca Scherzer; Donald P Kotler; Adrian S Dobs; Phyllis C Tien; Cora E Lewis; Richard A Kronmal; Steven B Heymsfield; Peter Bacchetti; Carl Grunfeld
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-02-10       Impact factor: 6.053

7.  Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates.

Authors:  Randall J Bateman; Ling Y Munsell; Xianghong Chen; David M Holtzman; Kevin E Yarasheski
Journal:  J Am Soc Mass Spectrom       Date:  2007-02-22       Impact factor: 3.109

8.  Age attenuates leucine oxidation after eccentric exercise.

Authors:  E L Kullman; W W Campbell; R K Krishnan; K E Yarasheski; W J Evans; J P Kirwan
Journal:  Int J Sports Med       Date:  2013-01-16       Impact factor: 3.118

Review 9.  Biomedical consequences of alcohol use disorders in the HIV-infected host.

Authors:  Patricia E Molina; Gregory J Bagby; Steve Nelson
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

10.  Hormonal regulators of muscle and metabolism in aging (HORMA): design and conduct of a complex, double masked multicenter trial.

Authors:  E Todd Schroeder; Carmen Castaneda-Sceppa; Ying Wang; Ellen F Binder; Miwa Kawakubo; Yolanda Stewart; Thomas Storer; Ronenn Roubenoff; Shalender Bhasin; Kevin E Yarasheski; Fred R Sattler; Stanley P Azen
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.